About: Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

clinical trial

Attributes	Values
rdf:type	Item
description	clinical trial (en) ensayu clínicu (ast) klinisch onderzoek (nl) клінічне випробування (uk)
rdfs:label	Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder (en) Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder (nl)
skos:prefLabel	Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder (en) Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder (nl)
name	Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder (en) Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder (nl)
title	wds:Q66073065-EACAE5EF-8DFA-43D2-AE28-BEB3C859667C
title	A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With REL-1017 25 mg Daily and 50 mg Daily as Adjunctive Therapy in the Treatment of Patients Diagnosed With Major Depressive Disorder (en)
end time	wds:Q66073065-7BA6377E-ADBE-4CAF-B662-7EA14E332FF3
end time	2019-05-01 00:00:00Z (xsd:dateTime)
instance of	wds:Q66073065-4FBB0C05-E470-4E0B-B311-C5C14D11C3EE
instance of	clinical trial
start time	wds:Q66073065-F4D2A98A-C21E-41B0-8B70-A1018360908A
start time	2018-05-11 00:00:00Z (xsd:dateTime)
country	wds:Q66073065-E5111A44-4A9F-4BE6-9935-AC1D08662F7B
country	United States of America
research site	wds:Q66073065-3BEB2D43-A1E3-4D53-9F16-5DF79512C4D6 wds:Q66073065-C8F0EB43-181A-41EE-9CD4-CB5A4FF3FC27
research site	Collaborative Neuroscience Network Atlanta Center for Medical Research
minimum age	wds:Q66073065-1403958C-9E7B-4114-8EEF-5285B8B06FC7
minimum age	18 (xsd:decimal)
number of participants	wds:Q66073065-A99EA2E1-0297-49CF-B8B5-C43E8D6B8D9F
number of participants	60 (xsd:decimal)
maximum age	wds:Q66073065-6B927B9E-119E-4C5F-87D9-049A891255D2
maximum age	65 (xsd:decimal)
study type	wds:Q66073065-DAAC394C-485D-427B-9A78-55BEEFD7F9E9
study type	interventional study
ClinicalTrials.gov ID	wds:Q66073065-081A428B-84FC-4566-8D5C-9B445900B7C2
ClinicalTrials.gov ID	NCT03051256
clinical trial phase	wds:Q66073065-2A018DA5-C2A1-45E4-B559-C8F8D5AD77DD
clinical trial phase	phase II clinical trial
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q66073065

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software